CDP870

Known as: CDP870s, 870s, CDP, 870, CDP 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2002-2010
01220022010

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
BACKGROUND Tumour necrosis factor (TNF)-alpha inhibitors are beneficial for the treatment of rheumatoid arthritis (RA) in terms… (More)
  • figure 1
  • figure 3
  • figure 4
  • table 1
  • table 1
Is this relevant?
Review
2010
Review
2010
Tumor necrosis factor (TNF)-alpha is implicated in the same time in apoptosis and in cell proliferation. TNF-alpha not only acts… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND & AIMS To investigate the efficacy and safety of certolizumab pegol (a polyethylene-glycolated Fab' fragment of anti… (More)
Is this relevant?
Review
2005
Review
2005
Crohn's disease is a T helper type 1 response immune disease characterized by increased production of interleukin-12 tumor… (More)
Is this relevant?
2004
2004
BACKGROUND CDP870 is a PEGylated Fab' fragment of a humanized monoclonal antibody that neutralizes tumour necrosis factor-alpha… (More)
Is this relevant?
2004
2004
 
Is this relevant?
2003
2003
SAFETY OF CDP870, A PEGYLATED HUMANIZED ANTI-TNF ANTIBODY FRAGMENT, IN CROHN’S DISEASE Stefan Schreiber, M.D.*, Trevor Winter, M… (More)
Is this relevant?
2003
2003
SAFETY OF CDP870, A PEGYLATED HUMANIZED ANTI-TNF ANTIBODY FRAGMENT, IN CROHN’S DISEASE Stefan Schreiber, M.D.*, Trevor Winter, M… (More)
Is this relevant?
Review
2003
Review
2003
Tumour necrosis factor (TNF) plays an important role in mediating the inflammation of inflammatory bowel disease, in particular… (More)
Is this relevant?
2002
2002
OBJECTIVE Biological products that neutralize tumour necrosis factor alpha (TNF-alpha) are beneficial in rheumatoid arthritis (RA… (More)
Is this relevant?